Relay module for implant

Information

  • Patent Grant
  • 11745020
  • Patent Number
    11,745,020
  • Date Filed
    Friday, March 5, 2021
    3 years ago
  • Date Issued
    Tuesday, September 5, 2023
    a year ago
Abstract
An implementation provides a system that includes: a control module including a first antenna, the control module configured to generate a first radio frequency (RF) signal and transmit the first RF signal using the first antenna; an implantable lead module including a second antenna and at least one electrode configured to stimulate excitable tissue of a subject; and a relay module configured to receive the first RF signal; generate a second RF signal based on the first RF signal, the second RF signal encoding a stimulus waveform to be applied by the at least one electrodes of the implantable lead module to stimulate the excitable tissue of the subject; and transmit the second RF signal to the implantable lead module.
Description
BACKGROUND

Active implanted stimulation devices have been utilized for applications such as pacing, defibrillation, spinal and gastric stimulation. Such devices typically include wired electrodes on a lead module hardwired to an implanted pulse generator (IPG) that contains an internal battery that can be recharged periodically with an inductive coil recharging system.


SUMMARY

In one aspect, a system includes a control module including a first antenna, the control module being configured to generate a first radio frequency (RF) signal and transmit the first RF signal using the first antenna; an implantable lead module including a second antenna and at least one electrode configured to stimulate excitable tissue of a subject; and a relay module configured to: receive the first RF signal; generate a second RF signal based on the first RF signal with the second RF signal encoding a stimulus waveform to be applied to the electrodes of the implantable lead module to stimulate excitable tissue of a subject; and transmit the second RF signal, wherein the implantable lead module is configured to receive the second RF signal using the second antenna, generate the stimulus waveform from the received second RF signal, and apply the stimulus waveform to the excitable tissue of the subject.


Implementations of this and other aspects may include the following features: a control module which may include a programming interface to allow a user to adjust parameters of the stimulation waveform; a first antenna of the control module which may include a dipole antenna, a folded dipole antenna, a microstrip antenna, or a phased array of antennas.


The relay module may include: a receive antenna layer configured to receive the first RF signal transmitted by the first antenna of the control module; at least one dielectric insulating layer; and a transmit antenna layer separated from the receive antenna layer by the dielectric insulating layer, the transmit antenna layer being configured to transmit the second RF signal to the second antenna of the implantable lead module, the second RF signal being generated based on the first RF signal, and the second RF signal encoding a stimulus waveform to be applied by the at least one electrode of the implantable lead module to stimulate the excitable tissue of the subject.


The receive antenna layer of the relay module may include one of: a patch antenna, or a dipole antenna. The receive antenna layer may further include at least one quarter wavelength antenna. The transmit antenna layer of the relay module may include one of: a patch antenna, or a dipole antenna. The transmit antenna layer may further include at least one quarter wavelength antenna.


The relay module may further include a flexible circuit, wherein the flexible circuit may include a rectifier and a capacitor, and wherein the capacitor is coupled to the rectifier and configured to store a charge during an initial portion of the first RF signal. The flexible circuit may further include a counter configured to cause the flexible circuit to generate a trigger upon an end of the initial portion. The flexible circuit may further include an oscillator, coupled to the counter and configured to generate, upon the trigger, a carrier signal, and wherein the flexible circuit may modulate the carrier signal with a stimulus waveform encoded in the first RF signal to generate the second RF signal. The flexible circuit may be configured to generate the second RF signal based on the stimulus waveform during a stimulation portion of the first RF signal, wherein the second RF signal has a corresponding carrier frequency that is substantially identical to that of the first RF signal. The flexible circuit may further include a power amplifier configured to amplify the second RF signal, and wherein the transmit antenna layer may be configured to transmit the amplified second RF signal to the second antenna of the implantable lead module. The power amplifier may be powered by the charge stored in the capacitor during the initial portion of the first RF signal. The oscillator may be triggered by an amplitude shift keying in the first RF signal.


The first RF signal and the second RF signal may have respective carrier frequencies that may be within a range of about 800 MHz to about 6 GHz. The respective carrier frequencies of the first and second RF signals may be different.


The relay module may be placed exterior to the subject and the relay module may further include a battery. The relay module may be subcutaneously placed underneath the subject's skin. The relay module may be placed on the subject's skin. The relay module is placed on a wearable item.


The relay module may further include a position sensor configured to read positional information of the relay module. The position sensor comprises one of: a touch sensor, a gyroscope, or an accelerometer. The control module may be further configured to: receive the positional information from multiple relay modules; and choose a particular relay module to transmit the second RF signal to the implantable lead module, based on the positional information received, wherein the particular relay module chosen is better coupled to the implantable lead module than at least one other relay module.


In another aspect, a method of stimulating excitable tissue in a subject by using a relay module includes: transmitting a first RF signal from a first antenna on a control module; receiving, by the relay module, the first RF signal from the first antenna on the control module; generating, by the relay module, a second RF signal based on the first RF signal, the second RF signal containing power and encoding a stimulus waveform to be applied by the at least one electrodes of the implantable lead module to stimulate excitable tissue of the subject; transmitting, by the relay module, the second RF signal to an implantable lead module; receiving, by the implantable lead module the second RF signal; generating, by the implantable lead module the stimulation waveform; and applying, through at least one electrode on the implantable lead module, the stimulation waveform to the excitable tissue.


Implementations of this and other aspects may further include rectifying an initial portion of the first RF signal to provide energy to store a charge on the relay module; generating the second RF signal at an end of the initial portion; and amplifying the second RF signal by using the stored charge before transmitting the second RF signal.


The method may further include: generating the second RF signal based on a trigger caused by an amplitude shift keying in the first RF signal, the amplitude shift keying corresponding to the end of the initial portion of the first RF signal. The method may further include: generating the second RF signal based on a trigger caused by counting a number of cycles during the initial portion of the first RF signal.


The second RF pulse may include a portion to provide energy to power the implantable lead module. The method may further include: configuring polarity of at least one electrode of the implantable lead module based on a subsequent portion of the second RF signal that encodes polarity setting information of the at least one electrode.


The details of one or more implementations are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.





DESCRIPTION OF DRAWINGS


FIG. 1 shows an example of a wireless stimulation system including a relay module.



FIGS. 2A and 2B show example of a portable Microwave Field Stimulator (MFS) device.



FIG. 3 is a block diagram showing an example of implantable lead module.



FIGS. 4A-4C show examples of configurations of a relay module.



FIGS. 5A-5C show examples of configurations of a relay module with a flexible circuit.



FIG. 6 is a block diagram showing an example of a circuit, such as a flexible circuit, used on a relay module.



FIG. 7 is a block diagram showing another example of a circuit, such as a flexible circuit, used on the relay module.



FIG. 8 is a timing diagram showing examples of the first RF signal received at the relay module 130 and subsequent waveforms generated by the flexible circuit.



FIG. 9 is a flow chart showing an example process in which the wireless stimulation system selects a particular relay module.



FIG. 10 shows example of a configuration of the relay module with a position sensor.



FIG. 11 illustrates an example workflow of a wireless stimulation system with the relay module of FIG. 10.



FIG. 12A-E show example placements of the relay module.



FIG. 13A-L show example placements of the relay module as a wearable item.



FIG. 14A-14D show example configurations of a portable MFS device.



FIG. 15 depicts relay module in the configuration of a watch.





DETAILED DESCRIPTION


FIG. 1 shows an example of a wireless stimulation system including a relay module 130. The wireless stimulation system includes a control module, such as a portable microwave field simulator (MFS) device 100, the relay module 130, and an implantable lead module 140, which may be an implantable neural stimulator. In the example shown in FIG. 1, the lead module 140 is implanted in a subject, such as a human patient, or an animal.


The portable MFS device 100 includes an antenna 110. Antenna 110 may be configured to transmit a first radio frequency (RF) signal that propagates to relay module 130. The first RF signal may have a characteristic carrier frequency within a range from about 800 MHz to about 6 GHz.


As shown by FIG. 1, the relay module 130 may be placed subcutaneously under the skin of a subject. The first RF signal from antenna 110 may propagate through body boundary 120 to reach relay module 130. Relay module 130 may also be placed outside body boundary, for example, on the patent's skin topically. Relay module 130 may also be placed as a wearable item, as will be discussed in further detail later.


Relay module 130 may include a receive antenna 131 and a transmit antenna 132. Receive (Rx) antenna 131 is configured to receive the RF signal from antenna 110. The coupling between antenna 110 and Rx antenna 131 may be inductive, radiative, or any combinations thereof. The Rx antenna 131 may be coupled to transmit (Tx) antenna 132 by a dielectric insulating layer(s) and flexible circuits, as will be discussed in further detail below. The Tx antenna 132 transmits a second RF signal to an implantable lead module 140. The second RF signal may be derived from, or otherwise based on, the first RF signal and may or may not have the same characteristic carrier frequency of the first RF signal, as will be discussed in further detail below. A RF module 130 may use, for example, a conditioning circuit in combination with a power amplifier to shape and enhance the second RF signal before transmitting the second RF signal to implantable lead module 140, as will be discussed below in further detail.


An implantable lead module 140 has been implanted inside the body of a subject. The subject can be a live human or animal. The implantable lead module 140 is a passive device without an onboard power source, such as a battery. An implantable lead module 140 includes an antenna 141 configured to receive the second RF signal from antenna 132. The coupling between antenna 141 and Tx antenna 132 may be inductive, radiative, or any combinations thereof. The implantable lead module 140 includes one or more electrodes placed in close proximity to an excitable tissue, such as, for example, neural tissue. The second RF signal may contain energy to power the lead module 140, and may encode a stimulus waveform. The lead module 140 may generate the stimulus waveform from the second RF signal, and apply the stimulus waveform to the excitable tissue using the electrodes. Examples of the lead module 140 are described in, for example, U.S. patent application Ser. No. 13/584,618, filed on Aug. 13, 2012, the entire contents of which are incorporated herein by reference.



FIGS. 2A and 2B show examples of a portable Microwave Field Stimulator (MFS) device. A portable MFS device 100 may include a power system 201, a controller 202, a user interface (UI) 203, a feedback subsystem 204, and antenna 110. Examples of the MFS are described in, for example, U.S. patent application Ser. No. 13/584,618, filed on Aug. 13, 2012.


As illustrated by FIG. 2A, a power system 201 may include a battery, for example, a rechargeable power source such as, for example, a lithium-ion battery, a lithium polymer battery, etc. The power system 201 provides power to a portable MFS device 100.


The controller 202 can create the first RF signal to be transmitted from the antenna 110 to the relay module 130, which in turn may generate and transmit the second RF signal to the antenna 141 on the implantable lead module 140. As shown in FIG. 2A, the controller 202 may include memory 211, pulse generator 212, modulator 213, and amplifier 214.


Memory 211 may be local memory on board of the portable MFS device 100. Memory 211 may include any type of non-volatile memories, such as, for example, EEPROM, flash memory, etc. Memory 211 may store stimulation parameter settings, such as for example, pulse amplitude, waveform shape, repetition frequency, pulse duration, etc. Based on the stored stimulation parameter settings, pulse generator 212 may generate stimulation waveforms. Modulator 213 may generate a carrier frequency, for example, within a range from about 600 MHz to about 6 GHz. The stimulation waveforms generated by pulse generator 212 may modulate the carrier frequency. The resulting modulated carrier frequency signal may be amplified by amplifier 214 to generate the first RF signal to be transmitted by antenna 110.


The controller 202 may receive input from the UI 203 and the feedback subsystem 204. UI 203 may include a Bluetooth circuit board, or a USB interface connector. UI 203 may include a programmer interface for a user, such as a manufacturer's representative, to adjust stimulation parameters, such as, for example, stimulation frequency, pulse width, power amplitude, duration of treatment, waveform shape, pre-programmed options and patient reminders. The programming interface can cause the selected settings to be stored on memory 211 of controller 202. The selected settings are used to create, for example, the appropriate stimulation waveforms for driving the electrodes on implantable lead module 140.


Feedback subsystem 204 also may provide input to the controller 202 in creating the first RF signal. The feedback may be based on measurements of reflected power on antenna 110. The reflected power may indicate the coupling between antenna 110 and surrounding medium, as will be discussed in further detail in association with FIG. 10.


Antenna 110 may include a dipole antenna, a folded dipole antenna, a patch antenna, a microstrip antenna, or a phased array of antennas. Antenna 110 may be impedance matched to air to improve coupling efficiency with relay module 130. Antenna 110 can be located on the top of a flexible fixation housing that encloses the MFS circuitry connected with a low loss cable, or within the MFS enclosure, or remote from the MFS connected through a low loss cable.



FIG. 2A illustrates an implementation in which the antenna 110 is housed within the enclosure of the portable MFS device 100. The housing enclosure of portable MFS device 100 can be made of materials such as neoprene, or polyurethane, or other similar material with similar dielectric properties.


In another example, shown in FIG. 2B, antenna 110 may be located on the outside of the portable MFS device 100 within a separate encasement by which the MFS power is hardwired to the antenna by a low loss cable. The antenna 110 can be located as far as three feet from the relay module 130, or alternatively may be coupled directly to the skin in the proximity of the implanted lead module 140.



FIG. 3 is a block diagram showing an example of implantable lead module 140. Implantable lead module 140 is a passive device without an active power supply, such as a battery. Implantable lead module 140 may be an implantable neural stimulator. Implantable lead module 140 may include antenna 141, power management circuitry 310, passive charge balance circuitry 318, and electrodes 322.


Antenna 141 is configured to receive the second RF signal from antenna 132 on relay module 130. The Antenna 141 may be embedded as a dipole, a patch, a microstrip, folded dipole, other antenna configuration. The second RF signal may have a carrier frequency in the GHz range and contain electrical energy for powering the wireless implantable lead module 140 and for providing stimulation pulses to electrodes of implantable lead module. Once received by the antenna 141, the second RF signal is routed to power management circuitry 310 as the input signal.


Power management circuitry 310 is configured to rectify the input signal and convert it to a DC power source. For example, the power management circuitry 310 may include a diode rectification bridge and a capacitor. The rectification may utilize one or more full wave diode bridge rectifiers within the power management circuitry 310.


The DC power source provides power to the stimulation circuitry 311 and lead logic circuitry 313. Stimulation circuitry 311 may extract the stimulation waveforms from the received input signal. The stimulation waveforms may be shaped by pulse shaping RC timer circuitry 312 and then applied to the electrodes 322. Passive charge balancing circuitry 318 may balance charges applied at the electrodes. Lead logic circuitry 313 may detect a portion of the input signal containing polarity setting information for each electrode of the electrode array 322. This information may be used to set the polarity of electrode interface 314 controlling the polarity assignment of each electrode on electrodes 322. A particular electrode on the electrode array 322 may be implanted near target excitable tissue. The excitable tissue can be, for example, a cardiac tissue, a neural tissue, etc.



FIGS. 4A-4C show examples of configurations of a relay module 130. A relay module 130 may include encapsulation materials 400 and antenna layers 401, as shown by FIG. 4A. Encapsulation materials 400 may be any material that encapsulates relay module 130, such as most plastics. The antenna layers 401 may be encapsulated underneath encapsulation material 400.



FIG. 4B shows a profile view of one example of a layered configuration for the Rx antenna 131 and the Tx antenna 132. Rx 131 in FIG. 4B is a patch antenna formed by a layered structure of two conductor layers 404 and one insulator layer 405 in between. The conductor layers 404 may include any appropriate conducting metal, for example, copper, silver, etc. The insulator layer 405 may include insulating dielectric materials, such as, for example, porcelain, glass, and most plastics.


As discussed above, relay module 130 may be placed either in proximity of the tissue medium within a few millimeters or subcutaneously under the skin of a subject, such as a human or an animal. If placed outside the subject's body, the Rx antenna 131 may be coupled to the air and may be impedance-matched to the air. If placed subcutaneously, the Rx antenna 131 may still be coupled to the air since the skin layer covering the antenna is sufficiently thin, having minimal effect on the coupling efficiency between the antenna 110 and Rx antenna 131 of the relay module 130. The separation of the two conductor layers 404 and the electromagnetic properties of the insulator layer 405 may determine the resonant frequency of Rx antenna 131. Rx antenna 131 may generally be a quarter wavelength antenna at this resonant frequency.


The Tx antenna 132 in FIG. 4B is also a patch antenna formed by a layered structure of two conductor layers 404 and one insulator layer 405 in between. Likewise, the separation of the two conductor layers 404 and the electromagnetic properties of the insulator layer 405 may determine the resonant frequency of Tx antenna 132. Similarly, Tx antenna 131 may also be a quarter wavelength antenna at this resonant frequency. In contrast to the Rx antenna 131, which may be coupled to the air, Tx antenna 132 may be coupled to the tissue, especially when relay module 130 is placed subcutaneously. Tx antenna 132 may then be impedance matched to tissue to improve coupling efficiency when transmitting the second RF signal to implantable lead module 140 inside the subject's body. The transmitting metal layer may have a smaller surface area than the ground plane and may have a specific shape for improved coupling with surrounding tissue (e.g., if placed topically on the subject's skin). As illustrated, Tx antenna 132 in FIG. 4B is separated by another insulator layer 405 from Rx antenna 131.


Generally, a patch antenna may include a conducting material layer that serves as a conducting plane; a dielectric insulating plane the size of the conducting plane placed over the conducting layer; and another conducting layer, smaller than the ground plane, shaped in a desired pattern. If two patch antennas are separated by another insulating plane, as illustrated by FIG. 4B, the E-field of the transmit patch antenna does not interact with the E-field of the receive patch antenna on the other side of the relay module, when no edge-effects are present.



FIG. 4C shows a profile view of another configuration of Rx antenna 131 and Tx antenna 132 configured as dipole antennas. In this configuration, the Rx antenna 131 is formed by the shape and contour of the surface of one conductor layer 404 while the Tx antenna 132 is formed by the shape and contour of another conductor layer 404. The two conductor layers are separated by an insulator layer 405. The shape and contour of each conductor layer may generally determine the corresponding resonant frequency. In this configuration, the Rx antenna 131 and the Tx antenna may also be quarter-wavelength antennas at their respective resonant frequencies.


In FIGS. 4B and 4C, the ground plane of the Tx antenna 132 may face away from the active radiator of the antenna 110 and the transmitting surface of Tx antenna 132 may face towards tissue in order to improve the efficiency of the Tx antenna 132 in relaying energy to the antenna 141 on implantable module 140. Additionally, Rx antenna 132 may have a surface area much larger than antenna 141 on the implantable module 140. For example, in certain embodiments, the Rx antenna 132 may have surface area of four square centimeters or above, while the antenna 141 within the implanted lead module may have a surface area less than one tenth of a square centimeter. The Rx antenna 131 may thus capture a much larger portion of the flux of EM energy (for example, hundreds of times larger) and relay that energy to the antenna 141 through the relay module Tx antenna 132. Although FIGS. 4B and 4C respectively show a patch-on-patch configuration and a dipole-on-dipole configuration, other arrangements may be implemented, such as, for example, a patch-on-dipole or a dipole-on-patch configuration.



FIGS. 5A-5C show examples of configurations of a relay module 130 with a flexible circuit. The RF signal may be received by a Rx antenna 131 from the antenna 110. This received RF signal may be modulated and amplified via circuitry on a flexible circuit within the relay module 130. The flexible circuit may be implemented in a flexible circuit board substrate that is easily bendable within the body or on the surface of the skin. These electronics may be isolated from the antenna ground planes by a layer of insulation. A layer of conductive material may provide the interconnections to route the input signal from the Rx antenna 131 and send the conditioned and amplified signal out through the Tx antenna 132. This circuitry may include amplification and conditioning functions, as will be discussed in detail in association with FIGS. 6-8.


The flexible circuit may be placed relative to the Rx antenna 131 and the Tx antenna 132. For example, FIGS. 5A and 5B respectively show the front view and the profile view of a configuration in which the flex circuit 506, along with the components, are placed on the side of the antenna layers. In another example, FIG. 5C shows the profile view of another configuration in which the flexible circuit 506 and the surface mount (SMT) flexible circuit components 507 are placed in between the antenna layers. Additionally, although not shown, the flexible circuit may also be placed on the top or bottom of the antenna layers.


The relay module 130 may operate in two modes, a relay mode and a repeater mode. In relay mode, the relay module 130 may not alter the stimulation portion of the received first RF signal when transmitting the second RF signal to the implantable lead module 140. In the repeater mode, however, the relay module 130 may enhance the stimulation portion of the received first RF signal when transmitting the second RF signal to the implantable lead module 140.



FIG. 6 is a block diagram showing an example of a circuit, such as a flexible circuit, used on the relay module 130. In this mode, relay module 130 operates as an RF signal replicator to transmit the second RF signal at the same carrier frequency as the stimulus portion of the received first RF signal from the portable MFS device 100.


The first RF signal transmitted from the portable MFS device 100 contains two separate portions of encoded carrier waveforms. The first RF signal is received by Rx antenna 131 on relay module 130. A charging portion of the received first RF signal may contain a long (e.g., about 1 ms or above) burst of pulses at a carrier frequency. This charging portion may be the initial portion of a particular signal pattern to be repeated in the first RF signal. This charging portion is used to charge a power storage reservoir circuit including a capacitor 605 within the relay module 130. For example, the flexible circuit may contain a rectifier 601 to generate a DC power supply by rectifying and smoothing the initial portion of the received first RF signal. The DC power supply may store charges in, for example, capacitor 605. The stored charge may then be used to power subsequent operations of relay module 130. These subsequent operations may include, for example, subsequent transmission of the second RF signal that powers the electrodes on implantable lead module 140. Specifically, implantable lead module 140 is a passive device without a power supply. In contrast, some implementations of the relay module 130, however, may include a power source, such as a rechargeable battery. Once the second RF signal is received at the passive implantable lead module 140, it may be demodulated to provide the stimulation waveforms to be applied at the electrodes 322. As discussed above in association with FIG. 3, in some implementations, the second RF signal may also contain polarity setting information to be applied in assigning the polarity of each electrode of the electrode array 322. Details are discussed in U.S. patent application Ser. No. 13/584,618, filed on Aug. 13, 2012. Thus, by transmitting the second RF signal, derived from or otherwise based on the first RF signal transmitted from portable MFS device 100, relay module 130 of FIG. 6 can power a passive lead module 140.


A stimulation portion of the received first RF signal encodes stimulus waveforms. This stimulation portion may be the later portion of the signal pattern being repeated in the first RF signal. The stimulation portion of the first RF signal will be conditioned by stimulus conditioning circuitry 602 before transmission to implantable lead module 140. The stimulus waveforms may contain short (e.g., about 0.5 ms or shorter) bursts of pulses. A low-noise amplifier 603 detects the stimulation portion of the first RF signal from Rx antenna 131 and feeds the stimulation portion to a high power amplifier 604. In one implementation, the first RF signal contains amplitude shift keying to indicate the end of the initial portion (for charging, e.g., capacitor 605) and the start of the stimulation portion. The amplitude shift keying may cause the stimulus conditioning circuitry 602 to generate a trigger to allow DC power to be received from the stored charge in capacitor 605. In another implementation, the stimulus conditioning circuit may include a counter that is set to expire upon a pre-determined number of pulse wave cycles. When the counter counts the number of pulse cycles in the received first RF signal has reached the pre-determined threshold, the counter will expire and generate a trigger. Upon the trigger, stored charge in capacitor 605 may be harvested to power, for example, stimulus conditioning circuit 602, low-noise amplifier 603 and power amplifier 604. In either example implementation, the output from the power amplifier 604 drives the Tx antenna 132 to transmit the amplified stimulus waveform at the original carrier frequency to the implantable lead module 140. The stored charge can be recharged by the next repetition of the initial portion in the first RF signal received from portable MFS device 100.



FIG. 7 is a block diagram showing another example of a circuit, such as a flexible circuit, used on the relay module 130. In this mode, relay module 130 acts as an active modulated pulse transmitter. The modulator 600 can provide a carrier signal at a different frequency than the frequency of the first RF signal received from the portable MFS device 100. The first RF signal is received by the Rx antenna 131 coupled to air.


The first RF signal received from portable MFS device 100 by Rx antenna 131 contains two separate portions of encoded carrier waveforms. As discussed above, an initial portion of the first RF signal may contain a long (e.g., about 1 ms or above) burst of pulses at a carrier frequency. This initial portion is used to charge a power storage reservoir circuit including a capacitor 605 within the relay module 130. For example, the flexible circuit may contain a rectifier 601 to generate a DC power supply by rectifying and smoothing the initial portion of the first RF signal. The DC power supply may store charges in, for example, capacitor 605. The stored charge may then be used to power subsequent power subsequent operations of relay module 130. These subsequent operations may include, for example, subsequent transmission of the second RF signal that powers the electrodes on implantable lead module 140. As discussed above, implantable lead module 140 is a passive device without a power supply. In contrast, some implementations of the relay module 130, however, may include a power source, such as a rechargeable battery. Once the second RF signal is received at the passive implantable lead module 140, it may be demodulated to provide the stimulation waveforms to be applied at the electrodes 322. As discussed above in association with FIG. 3, in some implementations, the second RF signal may also contain polarity setting information to be applied in assigning the polarity of each electrode of electrodes 322. Details of discussed in U.S. patent application Ser. No. 13/584,618, filed on Aug. 13, 2012. Thus, by transmitting the second RF signal, derived from or otherwise based on the first RF signal transmitted from portable MFS device 100, relay module 130 of FIG. 7 can also power a passive lead module 140.


A stimulation portion of the first RF signal encodes stimulus waveforms. This stimulation portion may be a later portion in a pattern being repeated in the first RF signal. The simulations portion of the first RF signal will be conditioned by stimulus conditioning circuitry 602 and further modulated by TX modulator 700 before transmission to implantable lead module 140. The stimulus waveforms contain short (e.g., about 0.5 ms or shorter) bursts of pulses. In one implementation, the first RF signal contains amplitude shift keying to indicate the end of the initial portion (for charging, e.g., capacitor 605) and the start of the stimulation portion. The amplitude shift keying may cause the stimulus conditioning circuitry 602 to generate a trigger to allow DC power to be received from the stored charge in capacitor 605. In another implementation, the stimulus conditioning circuit may include a counter that is set to expire upon a pre-determined number of pulse wave cycles. When the counted number of pulse cycles in the received first RF signal has reached the pre-determined threshold, the counter will expire and generate a trigger. Upon the trigger, stored charge in capacitor 605 may be harvested to power, for example, Tx modulator 700 and power amplifier 604. In either example implementation, the stimulus waveform is mixed with a carrier frequency of Tx modulator, the result is fed to power amplifier 604, and the output from the power amplifier 604 drives the Tx antenna 132 to transmit the amplified stimulus waveform modulated at the carrier frequency of Tx modulator 132 to the implantable lead module 140. As discussed above, the stored charge can be recharged by the next instance of the initial portion of the first RF signal received from portable MFS device 100.


In this mode, the carrier frequency of the first RF signal transmitted by the portable MFS device 100 can be decoupled from the carrier frequency of the stimulus waveform transmitted by the relay module 130. As long as the two carrier frequencies are sufficiently apart and the pass band of antenna 141 on implantable lead module 140 is sufficiently selective, the electrodes on the implantable lead module may only be driven by the stimulus waveform transmitted from relay module 130.



FIG. 8 is a timing diagram showing examples of the first RF signal received at the relay module 130 and subsequent waveforms generated by the flexible circuit. For example, in microwave relay mode (illustrated in FIG. 6), the charging portion 801 utilized for charge storage may include a burst of pulses 1 millisecond or longer in pulse duration. Between each repetition of the charging portion of long bursts, a short burst, with pulse durations of 500 microseconds or less, encodes the stimulus waveforms. This portion is the stimulation portion 802. In one implementation, after every 1000 cycles of the short bursts, the stored power is recharged/replenished by the long bursts for pulse durations of 1 millisecond or longer. The cyclic pattern is repeated as needed to power the amplification circuitry on board the relay antenna module so that stimulus waveforms are sent to passive, implantable lead module 140.


Multiple implantable lead modules 140 may be implanted inside a subject's body. Multiple relay modules 130 may be configured to relay energy from a portable MFS device 100 to the implantable lead modules 140.



FIG. 9 is a flow chart 900 showing an example process in which the wireless stimulation system chooses a particular relay module for relaying energy to a particular implantable lead module 140.


Initially, a user may input stimulation parameters into the portable MFS device 100 (902). The stimulation parameters may include, for example, frequency, amplitude, pulse width, treatment duration, etc. These parameters may be entered into portable MFS device 100 through a programmer module, e.g., UI 203 (904). Afterwards, the portable MFS device 100 may send power to each relay module 130 (906). As discussed below in FIGS. 10 and 11, each relay module 130 may include position sensors to provide positional information of the respective relay module 130. Example position sensors may include radio-frequency identification (RFID) devices, touch sensors, gyroscopes, etc.


Subsequently, the portable MFS device 100 may read the positional information generated by the position sensors at the respective relay module 130 (908). Based on the positional information collected, portable MFS device 100 may determine the relay module 130 best positioned to relay energy to power a particular implantable lead module 140. The relay module best positioned to relay energy may be the relay module with one of the following characteristics: the lowest amount of transmission loss, best coupling to tissue, closest proximity to the portable MFS device 100, or closest proximity to a particular implantable lead module 140. For example, a software algorithm may be implemented on the portable MFS device 100 to determine the position of a particular relay module 130 relative to a given implanted implantable lead module 130. The portable MFS device 100 may then determine which relay module should be selected to transmit energy most efficiently to the given implanted implantable lead module 130. In this example, the relay module that will transmit energy most efficiently to the given implantable lead module may be the relay module closest to the given implantable lead module. The portable MFS device 100 can digitally control a multiplexor to selectively transmit energy to a chosen relay module 130.


Thereafter, the portable MFS device 100 may generate the first RF signal by modulating a carrier signal with a particular stimulation waveform, for example, according to stimulation parameters stored in memory 211 (910). The portable MFS device 100 may then send the first RF signal to the optimal relay module as determined above (911). The selected optimal relay module may be the only relay module activated to receive the first RF signal. The activation may be achieved remotely by portable MFS device 100 before transmission of the first RF signal.


When the selected optimal relay module receives the first RF signal at its Rx antenna 131, the relay module may utilize a charging portion of the received first RF signal to charge a reservoir, such as, for example, capacitor 605, and then utilize the stored charge to power the relay circuitry (912). For example, the stored charge may be used to modulate a carrier wave with a stimulation waveform, amplifier the modulated carrier wave to provide the second RF signal, and then transmit the second RF signal to the given implantable lead module (914).


Subsequently, the given implantable lead module receives the second RF signal. As a passive device, the given implantable lead module is powered by the energy contained in the second RF signal and extracts the stimulation waveform from the received second RF signal (916). In capturing the energy contained in the second RF signal, the implantable lead module 140 may store a charge in a capacitor. The stored charge will be utilized to apply the extracted stimulation waveform to the electrodes 322 (918).



FIG. 10 shows an example of a configuration of a relay module 130 with a position sensor 1000. As illustrated, position sensor 1000 may be integrated on flexible circuit 506. As shown in the left panel of FIG. 10, the flexible circuit 506 may be placed on top of antenna layers 401 and occupying part of the surface area of antenna layers 401. Encapsulation material 400 may enclose flexible circuit 506 (with components) and antenna layers 401, as discussed above.


The right panel shows a profile view of the example configuration of relay module 130 with positional sensor 1000. Position sensor 1000 may be a component of the surface mount (SMT) components 507 mounted on flexible circuit 506. As discussed above, the Rx antenna 131 and the Tx antenna 132 may be implemented as patch-on-patch antennas. The Tx antenna 132 of each relay module 130 can be circularly polarized to substantially obviate directional dependence, thereby permitting a wider acceptance angle at the antenna 141 on implantable lead module 140.


In one implementation, a semiconductor gyroscope can be used as a position sensor to determine the orientation of Rx antenna 131 and Tx antenna 132. In other implementations, touch sensors can be used as a position sensor to detect, for example, if the Tx antenna 132 of the relay module 130 is coming in contact with an object. The touch sensor may also detect any force gradients to determine whether the side of Tx antenna 132 is touching something pliable, such as clothing, or something hard. In particular, when Tx antenna 132 is touching a lossy surface, like the thigh, it could be considered a worst case scenario. A lossy surface may have different impedance than the impedance of the antenna. When the Rx antenna 131 or the Tx antenna 132 is touching a side pocket material, or other clothing, antenna coupling could be closer to that of air coupling, which may be considered the best-case scenario.


In yet other implementations, an additional coupler can be used to detect the forward power and reflection outputted by a given Tx antenna 132. A lossy surface may be detected when the measured reflection measurement is high, such as, for example, over 25% of the transmission energy. The presence of a lossy surface on a particular relay module may provide feedback to portable MFS device 100 that the particular relay module should be avoided. As a result, an alert may be provided to UI 203 on portable MFS device 100 to notify a user of the situation. Unless the situation has been remedied, the portable MFS device 100 may refrain from using the given relay module to relay energy to an implantable lead module.



FIG. 11 illustrates an example workflow of a wireless stimulation system with the relay module 130 of FIG. 10. In step 1, the portable MFS device 100 transmits omnidirectional charging signal to all relay modules in range. In step 2, position sensors on the relay module 130 provide positional readings for the host relay module and utilize a telemetry antenna within the relay module to transmit the positional information to the portable MFS device as a feedback signal from the position sensors. In some implementations, Rx antenna 131 may serve as a transceiver to transmit the telemetry signal to the portable MFS device 100. In these implementations, relay module 130 may include a power source, such as, for example, a rechargeable battery. In step 3, the portable MFS device 100 receives the information from the position sensors on the respective relay modules. Based on the positional information received, the portable MFS device 100 software algorithms determine which relay module 130 is in the most optimal position to relay the maximum amount of energy to power a given implantable lead module 140 that has already been implanted in the subject, as discussed above. In step 4, portable MFS device 100 sends energy directed to the chosen relay module 130. Thereafter, the relay module 130 harvests the energy to power the given implantable lead module 140, as discussed above.



FIG. 12A-E show example placements of the relay module. The relay module 130 can be placed nearby a variety of anatomical targets that contain the implanted lead module. Example targeted sites for relay module 130 include, but are not limited to, behind the neck or at the small of the back as shown in FIG. 12A; the waistline or abdomen, as shown in FIG. 12B; the side of the buttock as shown in FIG. 12C. The relay module 130 may also be placed under the skin in the skullcap, as illustrated in FIG. 12D, and just under the skin over the vagus nerve around the neck area, as illustrated in FIG. 12E.



FIGS. 13A-L show example placements of the relay module as a wearable item. Relay module 130 may be placed, for example, a bandage, a strap, an adhesive surface, a sleeve cover, or a piece of cloth worn on the body, for instance behind the neck or at the small of the back. FIG. 13A shows an example placement of relay module 130 in an eyeglass frame 1301. FIG. 13B depicts a dress shirt 1310 with relay modules 130 attached to the inside and outside. FIG. 13C depicts relay module 130 placed on the inside and outside of a general use shirt 1320. FIG. 13D depicts an example placement of relay module 130 in a neck brace or other stabilization brace 1330. FIG. 13E shows example placement of relay module 130 in a ball cap 1340. FIG. 13F shows example placement of relay module 130 PR on a flexible ace bandage 1350 housing which can be utilized at a multitude of locations on the body. FIG. 13G shows example placement of relay module 130 on an ankle brace 1360. FIG. 13H d shows an example of placing relay module 130 within a girdle or haulter 1370. FIG. 13I shows example placement of relay module 130 on the body of a bra structure 1380. FIG. 13J shows example placement of relay module 130 on trunks 1390. FIG. 13K depicts example placement of relay module 130 in multiple locations on a leg brace 1391. FIG. 13L depicts example placement of relay module 130 within a scarf material 1392.


The design of the relay module 130 is intended to be convenient for patient use in daily activities such as exercise, working, and other leisure activities. A strap holding the relay module 130 over an implanted antenna 141 on implantable lead module 140 can become inconvenient in situations such as swimming, such as where the relay module 130 can shift, for example, during the sleeping time of the subject; or where the relay module 130 could press against the skin potentially uncomfortably. Additionally, bulky medical devices tend to be unaesthetic and are undesirable in many situations where skin is exposed.


The implementations discussed above address these issues by placing the pulse generator on the portable MFS device 100 wirelessly away from the body up to three feet. The implementations utilize a compact relay module 130 that may seamlessly integrate into a wearable item or be subcutaneously placed. The relay module 130 may relay energy received from portable MFS device 100 to power implantable lead module 140. Some implementations may further detect which relay module is in contact with lossy materials and guides the pulsed microwave energy from portable MFS device 100 to be directed to the relay module with the best coupling to a particular implantable lead module.



FIG. 14A-14D show example configurations of a portable MFS device. As discussed above, the portable MFS device 100 may be typically located outside the body and is not physically connected to the skin; however can be located subcutaneously (not shown). In certain embodiments, a programmer is embedded into the portable MFS device 100 that interfaces with a user to provide options to change the frequency, amplitude, pulse width, treatment duration, and other system specifications. In certain circumstances, a manufacturer's representative will set specific parameters for the MFS device and the patient will be given the option to adjust certain subsets of those parameters, within a specified range, based on a user's experience.



FIG. 14A shows an example portable MFS device 100 with a strap 1401, surface 1402, and control buttons 1403-1406 for a user to make adjustments to the stimulation parameters. Antenna 110 may be mounted under surface 1402. FIG. 14B shows another example portable MFS device 100 with a display 1410 on surface 1402, and control buttons 1405 and 1406. Antenna 110 may be mounted under surface 1402. The display 1410 may provide visual information to a user about the progress of the therapy and associated stimulation parameters. Control buttons 1405 and 1406 may allow a user to make adjustments to the stimulation parameters. FIG. 14C shows yet another example portable MFS device 100 with a surface 1402, and control buttons 1403 to 1406. Antenna 110 may be mounted under surface 1402. Control buttons 1403-1406 may allow a user to make adjustments to the stimulation parameters. FIG. 14D shows still another example portable MFS device 100 with antenna 110 and control buttons 1403-1406 for a user to make adjustments to the stimulation parameters.



FIG. 15 depicts the MFS and Tx antenna in the configuration of a watch or other strap on arm unit. In certain embodiments, the Tx antenna is located on the perimeter of the watch face, or optionally on the strap of the watch or arm unit.


A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made. Accordingly, other implementations are within the scope of the following claims.

Claims
  • 1. A system comprising a wirelessly powered relay device, wherein the wirelessly powered relay device comprising: a receiver antenna layer configured to receive a first radio-frequency (RF) signal transmitted by a first antenna of a control device, wherein the first RF signal contains electrical energy;at least one dielectric insulating layer; anda transmitter antenna layer separated from the receiver antenna layer by the dielectric insulating layer, wherein the transmitter antenna layer is configured to transmit a second RF signal, and the second RF signal is generated using the electrical energy contained in the first RF signal.
  • 2. The system of claim 1, wherein the receiver antenna layer of the wirelessly powered relay device further comprises one of: a patch antenna, or a dipole antenna, wherein the transmitter antenna layer of the wirelessly powered relay device further comprises one of: a patch antenna, or a dipole antenna.
  • 3. The system of claim 1, wherein the wirelessly powered relay device further comprises a flexible circuit, wherein the flexible circuit comprises a rectifier and a capacitor, and wherein the capacitor is coupled to the rectifier and configured to store a charge during an initial portion of the first RF signal.
  • 4. The system of claim 3, wherein the flexible circuit further comprises a counter configured to cause the flexible circuit to generate a trigger upon an end of the initial portion.
  • 5. The system of claim 4, wherein the flexible circuit further comprises an oscillator, coupled to the counter and configured to generate, upon the trigger, a carrier signal, and wherein the flexible circuit modulates the carrier signal with a stimulus waveform encoded in the first RF signal to generate the second RF signal.
  • 6. The system of claim 5, wherein the flexible circuit is configured to generate the second RF signal based on the stimulus waveform during a stimulation portion of the first RF signal, wherein the second RF signal has a corresponding carrier frequency that is substantially identical to that of the first RF signal.
  • 7. The system of claim 5, wherein the flexible circuit further comprises a power amplifier configured to amplify the second RF signal solely using charges accumulated in the capacitor during the initial portion of the first RF signal, and wherein the transmitter antenna layer is configured to transmit the amplified second RF signal via non-inductive coupling to a second antenna on an implantable stimulator device.
  • 8. The system of claim 7, wherein the power amplifier is configurable to be powered by the charge stored in the capacitor during the initial portion of the first RF signal.
  • 9. The system of claim 5, wherein the oscillator is configurable to be triggered by an amplitude shift keying in the first RF signal.
  • 10. The system of claim 1, wherein the receiver antenna layer comprises at least one quarter wavelength antenna, wherein the transmitter antenna layer comprises at least one quarter wavelength antenna.
  • 11. The system of claim 1, wherein the wirelessly powered relay device is configured to generate the second RF signal during a stimulation portion of the first RF signal and by using a charge accumulated on the wirelessly powered relay device during an initial portion of the first RF signal, wherein the initial portion precedes the stimulation portion, and wherein the second RF signal encodes a stimulus waveform.
  • 12. The system of claim 1, wherein the wirelessly powered relay device is sized and shaped to be placed outside a subject receiving an implantable stimulator device.
  • 13. The system of claim 12, further comprising: an implantable stimulator device comprising a second antenna and at least one electrode, wherein the implantable stimulator device is configured to receive the second RF signal using the second antenna, extract a stimulus waveform from the received second RF signal, and apply the stimulus waveform to a neural tissue of the subject using the at least one electrode.
  • 14. The system of claim 1, further comprising: a control device comprising the first antenna, wherein the control device is configured to generate the RF signal and transmit the first RF signal using the first antenna.
  • 15. The system of claim 14, wherein the control device further comprises a programming interface to allow a user to adjust parameters of a stimulus waveform.
  • 16. The system of claim 14, wherein the first antenna of the control device comprises one of: a dipole antenna, folded dipole antenna, microstrip antenna, or a phased array of antennas.
  • 17. The system of claim 14, wherein the control device is configured to transmit the first RF signal at a first carrier frequency, and wherein the wirelessly powered relay device is configured to transmit the second RF signal at a second carrier frequency, and wherein both the first carrier frequency and the second carrier frequency are within a range of about 800 MHz to about 6 GHz.
  • 18. The system of claim 17, wherein the first carrier frequency and the second carrier frequency are configurable to differ from each other.
  • 19. A system, comprising: a control module comprising a first antenna, the control module configured to generate a first radio frequency (RF) signal and transmit the first RF signal using the first antenna,an implantable lead module comprising a second antenna and at least one electrode, the at least one electrode being configured to stimulate an excitable tissue of a subject; anda relay module configured to: receive the first RF signal;generate a second RF signal based on the first RF signal, the second RF signal encoding a stimulus waveform to be applied by the at least one electrode of the implantable lead module to stimulate the excitable tissue of the subject; andtransmit the second RF signal,wherein the relay module comprises: a receive antenna layer configured to receive the first RF signal transmitted by the first antenna of the control module;at least one dielectric insulation layer; anda transmit antenna layer separated from the receive antenna layer by the dielectric insulating layer, the transmit antenna layer being configured to transmit the second RF signal to the second antenna of the implantable lead module, the second RF signal being generated based on the first RF signal, and the second RF signal encoding a stimulus waveform being applied by the at least one electrode of the implantable lead module to stimulate the excitable tissue of the subject,wherein the implantable lead module is configured to receive the second RF signal using the second antenna, generate the stimulus waveform from the received second RF signal, and apply the stimulus waveform to the excitable tissue of the subject.
  • 20. The system of claim 19, wherein the control module further comprises: a programming interface to allow a user to adjust parameters of the stimulus waveform.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 15/983,355, filed May 18, 2018, now allowed, which is a continuation of U.S. application Ser. No. 15/002,610, filed Jan. 21, 2016, now U.S. Pat. No. 9,974,965, issued May 22, 2018, which is a continuation of U.S. application Ser. No. 13/621,530, filed Sep. 17, 2012, now U.S. Pat. No. 9,242,103, issued Jan. 26, 2016, which claims the benefit of U.S. Provisional Application No. 61/535,295, filed Sep. 15, 2011, the entire contents of which are hereby incorporated by reference.

US Referenced Citations (303)
Number Name Date Kind
2990547 McDougal Jun 1961 A
3662758 Glover May 1972 A
3663758 Erbert May 1972 A
3727616 Lenzkes Apr 1973 A
4057069 Dorffer et al. Nov 1977 A
4102344 Conway et al. Jul 1978 A
4223679 Schulman et al. Sep 1980 A
4494950 Fischell Jan 1985 A
4524774 Hildebrandt Jun 1985 A
4525774 Kino et al. Jun 1985 A
4532930 Crosby Aug 1985 A
4561443 Hogrefe et al. Dec 1985 A
4592359 Galbraith Jun 1986 A
4612934 Borkan Sep 1986 A
4628933 Michelson Dec 1986 A
4665896 LaForge May 1987 A
4726378 Kaplan Feb 1988 A
4736747 Drake Apr 1988 A
4736752 Munck Apr 1988 A
4741339 Harrison et al. May 1988 A
4750499 Hoffer Jun 1988 A
4793353 Borkan Dec 1988 A
4837049 Byers et al. Jun 1989 A
4926879 Sevrain May 1990 A
4947844 McDermott Aug 1990 A
5058581 Silvian Oct 1991 A
5070535 Hochmair et al. Dec 1991 A
5193539 Schulman et al. Mar 1993 A
5262793 Sperry Nov 1993 A
5314458 Najafi et al. May 1994 A
5343766 Lee Sep 1994 A
5358514 Schulman et al. Oct 1994 A
5411535 Fujii et al. May 1995 A
5583510 Ponnapalli et al. Dec 1996 A
5591217 Barreras Jan 1997 A
5626630 Markowitz et al. May 1997 A
5735887 Barreras, Sr. et al. Apr 1998 A
5769877 Barreras Jun 1998 A
5861019 Sun et al. Jan 1999 A
5991664 Seligman Nov 1999 A
5995874 Borza Nov 1999 A
6141588 Cox et al. Oct 2000 A
6164284 Shulman et al. Dec 2000 A
6175752 Say et al. Jan 2001 B1
6350335 Hampel et al. Feb 2002 B1
6364889 Kheiri et al. Apr 2002 B1
6415184 Ishikawa et al. Jul 2002 B1
6445953 Bulkes et al. Sep 2002 B1
6445955 Michelson et al. Sep 2002 B1
6458157 Suaning Oct 2002 B1
6463336 Mawhinney Oct 2002 B1
D466487 Wada et al. Dec 2002 S
6516227 Meadows et al. Feb 2003 B1
D474982 Wilson May 2003 S
6564807 Schulman et al. May 2003 B1
6611715 Boveja Aug 2003 B1
6615081 Boveja Sep 2003 B1
6647296 Fischell et al. Nov 2003 B2
6662052 Sarwal et al. Dec 2003 B1
6684104 Gordon et al. Jan 2004 B2
6690974 Archer et al. Feb 2004 B2
6889086 Mass et al. May 2005 B2
6895280 Meadows et al. May 2005 B2
6972727 West et al. Dec 2005 B1
7003350 Denker et al. Feb 2006 B2
7027874 Sawan et al. Apr 2006 B1
7110823 Whitehurst et al. Sep 2006 B2
D529402 Burton Oct 2006 S
7177690 Woods et al. Feb 2007 B2
7214189 Zdeblick May 2007 B2
7277728 Kauhanen Oct 2007 B1
7283875 Larsson Oct 2007 B2
7317947 Wahlstrand et al. Jan 2008 B2
7436752 He Oct 2008 B2
7450992 Cameron Nov 2008 B1
7471257 Candal et al. Dec 2008 B2
7489248 Gengel et al. Feb 2009 B2
7616991 Mann et al. Nov 2009 B2
7620451 Demarais Nov 2009 B2
7630771 Cauller Dec 2009 B2
7664552 Wahlstrand et al. Feb 2010 B2
D612543 Marseille Mar 2010 S
7729781 Swoyer et al. Jun 2010 B2
7738964 Von Arx et al. Jun 2010 B2
7741734 Joannopoulos et al. Jun 2010 B2
7765013 Blick et al. Jul 2010 B2
7853333 Demarais Dec 2010 B2
7869885 Begnaud et al. Jan 2011 B2
7894905 Pless et al. Feb 2011 B2
7904170 Harding Mar 2011 B2
7908014 Schulman et al. Mar 2011 B2
7917226 Nghiem et al. Mar 2011 B2
7939346 Blick et al. May 2011 B2
D658302 Nixon Apr 2012 S
8170672 Weiss et al. May 2012 B2
8242968 Conrad et al. Aug 2012 B2
8320850 Khlat Nov 2012 B1
8332040 Winstrom Dec 2012 B1
8634928 O'Drisco et al. Jan 2014 B1
D701504 Christopher et al. Mar 2014 S
D703204 Riddiford et al. Apr 2014 S
D714288 Aumiller et al. Sep 2014 S
8849412 Perryman et al. Sep 2014 B2
8903502 Perryman Dec 2014 B2
D721701 Al-Nasser Jan 2015 S
D725071 Lee et al. Mar 2015 S
D725072 Kim et al. Mar 2015 S
D725652 Ishii Mar 2015 S
D734330 Huang et al. Jul 2015 S
9199089 Perryman et al. Dec 2015 B2
9220897 Perryman et al. Dec 2015 B2
9242103 Perryman Jan 2016 B2
9254393 Perryman et al. Feb 2016 B2
9409030 Perryman et al. Aug 2016 B2
9566449 Perryman et al. Feb 2017 B2
9757571 Perryman Sep 2017 B2
9789314 Perryman Oct 2017 B2
9925384 Perryman et al. Mar 2018 B2
9974965 Perryman May 2018 B2
10238874 Perryman Mar 2019 B2
10293169 Perryman et al. May 2019 B2
10315039 Perryman et al. Jun 2019 B2
10420947 Larson et al. Sep 2019 B2
10471262 Perryman et al. Nov 2019 B2
10953228 Perryman et al. Mar 2021 B2
20010010662 Saitou et al. Aug 2001 A1
20020058972 Minogue et al. May 2002 A1
20020082668 Ingman Jun 2002 A1
20020091420 Minogue et al. Jul 2002 A1
20020095195 Mass Jul 2002 A1
20020103513 Minogue et al. Aug 2002 A1
20020123779 Von Arx et al. Sep 2002 A1
20020128686 Minogue et al. Sep 2002 A1
20020128693 Minogue et al. Sep 2002 A1
20020133195 Minogue et al. Sep 2002 A1
20030078633 Firlik et al. Apr 2003 A1
20030114898 Von Arx et al. Jun 2003 A1
20030114899 Woods et al. Jun 2003 A1
20030139782 Duncan et al. Jul 2003 A1
20030169207 Beigel Sep 2003 A1
20030204224 Torgerson et al. Oct 2003 A1
20040044385 Fenn et al. Mar 2004 A1
20040059392 Parramon et al. Mar 2004 A1
20040082979 Tong et al. Apr 2004 A1
20040127942 Yomtov et al. Jul 2004 A1
20040138723 Malick et al. Jul 2004 A1
20040167587 Thompson et al. Aug 2004 A1
20040176803 Whelan et al. Sep 2004 A1
20040220621 Zhou Nov 2004 A1
20040230263 Samulski Nov 2004 A1
20040243208 Jordan Dec 2004 A1
20050027207 Westbrook et al. Feb 2005 A1
20050119716 McClure et al. Jun 2005 A1
20050137668 Khan Jun 2005 A1
20050245994 Varrichio et al. Nov 2005 A1
20060001583 Bisig Jan 2006 A1
20060003721 Bisig Jan 2006 A1
20060047327 Colvin et al. Mar 2006 A1
20060085039 Hastings et al. Apr 2006 A1
20060085042 Hastings et al. Apr 2006 A1
20060149331 Man et al. Jul 2006 A1
20060161216 Constance Jul 2006 A1
20060161225 Sormann et al. Jul 2006 A1
20060178718 Jordan Aug 2006 A1
20060206168 Minogue et al. Sep 2006 A1
20060287686 Cullen et al. Dec 2006 A1
20060289528 Chiu et al. Dec 2006 A1
20070055322 Forsberg et al. Mar 2007 A1
20070055324 Thompson et al. Mar 2007 A1
20070066995 Strother et al. Mar 2007 A1
20070100385 Rawat May 2007 A1
20070100395 Ibrahim May 2007 A1
20070100935 Miyazaki et al. May 2007 A1
20070106337 Errico et al. May 2007 A1
20070109208 Turner May 2007 A1
20070112402 Grill et al. May 2007 A1
20070123948 Dal Molin May 2007 A1
20070156179 S.E. Jul 2007 A1
20070208394 King et al. Sep 2007 A1
20070213773 Hill et al. Sep 2007 A1
20070213783 Pless Sep 2007 A1
20070239224 Bennett et al. Oct 2007 A1
20070254632 Beadle et al. Nov 2007 A1
20070255223 Phillips et al. Nov 2007 A1
20070255373 Metzler et al. Nov 2007 A1
20070257636 Phillips et al. Nov 2007 A1
20070265543 VanSickle et al. Nov 2007 A1
20070265690 Lichtenstein et al. Nov 2007 A1
20070288066 Christman et al. Dec 2007 A1
20070293909 Cowan et al. Dec 2007 A1
20080010358 Jin Jan 2008 A1
20080046012 Covalin et al. Feb 2008 A1
20080077184 Denker et al. Mar 2008 A1
20080077188 Denker et al. Mar 2008 A1
20080077189 Ostroff Mar 2008 A1
20080103558 Wenzel May 2008 A1
20080154217 Carrez et al. Jun 2008 A1
20080161883 Conor Jul 2008 A1
20080266123 Ales et al. Oct 2008 A1
20080279896 Heinen et al. Nov 2008 A1
20080281244 Jacobs Nov 2008 A1
20090018599 Hastings et al. Jan 2009 A1
20090099405 Schneider et al. Apr 2009 A1
20090105784 Massoud-Ansari Apr 2009 A1
20090105795 Minogue et al. Apr 2009 A1
20090125091 Schoenbach et al. May 2009 A1
20090132002 Kieval May 2009 A1
20090132003 Borgens et al. May 2009 A1
20090200985 Zane et al. Aug 2009 A1
20090204170 Hastings et al. Aug 2009 A1
20090234407 Hastings et al. Sep 2009 A1
20090248112 Mumbru et al. Oct 2009 A1
20090251101 Phillips et al. Oct 2009 A1
20090270948 Nghiem et al. Oct 2009 A1
20090270951 Kallmyer Oct 2009 A1
20090292339 Erickson Nov 2009 A1
20100010565 Lichtenstein et al. Jan 2010 A1
20100053789 Duric et al. Mar 2010 A1
20100114143 Albrecht et al. May 2010 A1
20100114198 Donofrio et al. May 2010 A1
20100125269 Emmons et al. May 2010 A1
20100125312 Stevenson et al. May 2010 A1
20100137938 Kishawi et al. Jun 2010 A1
20100168818 Barror et al. Jul 2010 A1
20100174340 Simon Jul 2010 A1
20100179449 Chow et al. Jul 2010 A1
20100198039 Towe Aug 2010 A1
20100198307 Toy et al. Aug 2010 A1
20100231382 Tayrani et al. Sep 2010 A1
20100234919 Minogue et al. Sep 2010 A1
20100234922 Forsell Sep 2010 A1
20100241051 Dacey, Jr. et al. Sep 2010 A1
20100268298 Moffitt et al. Oct 2010 A1
20100269339 Dye et al. Oct 2010 A1
20100298742 Perlman et al. Nov 2010 A1
20100331934 McDonald et al. Dec 2010 A1
20110029043 Frysz et al. Feb 2011 A1
20110040350 Griffith Feb 2011 A1
20110054563 Janzig et al. Mar 2011 A1
20110074342 MacLaughlin Mar 2011 A1
20110077698 Tsampazis et al. Mar 2011 A1
20110098583 Pandia et al. Apr 2011 A1
20110106220 DeGiorgio et al. May 2011 A1
20110120822 Kondou et al. May 2011 A1
20110121822 Parsche May 2011 A1
20110125214 Goetz et al. May 2011 A1
20110130804 Lin et al. Jun 2011 A1
20110144468 Boggs et al. Jun 2011 A1
20110152750 Dacey, Jr. et al. Jun 2011 A1
20110166630 Phillips et al. Jul 2011 A1
20110172733 Lima et al. Jul 2011 A1
20110190849 Faltys et al. Aug 2011 A1
20110208266 Minogue et al. Aug 2011 A1
20110245892 Kast et al. Oct 2011 A1
20110276108 Crowe et al. Nov 2011 A1
20120004708 Chen et al. Jan 2012 A1
20120004709 Chen et al. Jan 2012 A1
20120116477 Crowe et al. May 2012 A1
20120143282 Fukui et al. Jun 2012 A1
20120158407 Forsell Jun 2012 A1
20120194399 Bily et al. Aug 2012 A1
20120215218 Lipani Aug 2012 A1
20120239107 Kallmyer Sep 2012 A1
20120283800 Perryman et al. Nov 2012 A1
20120302821 Burnett Nov 2012 A1
20120330384 Perryman et al. Dec 2012 A1
20130016016 Lin et al. Jan 2013 A1
20130066400 Perryman et al. Mar 2013 A1
20130079849 Perryman et al. Mar 2013 A1
20130131752 Rawat May 2013 A1
20130018439 Chow et al. Jun 2013 A1
20130165991 Kim Jun 2013 A1
20130226262 Stevenson et al. Aug 2013 A1
20130310901 Perryman et al. Nov 2013 A1
20140031837 Perryman et al. Jan 2014 A1
20140047713 Singh et al. Feb 2014 A1
20140058480 Perryman et al. Feb 2014 A1
20140058481 Perryman et al. Feb 2014 A1
20140169142 Heck et al. Jun 2014 A1
20140266935 Tankiewicz Sep 2014 A1
20140336727 Perryman et al. Nov 2014 A1
20150182753 Harris et al. Jul 2015 A1
20150321017 Perryman et al. Nov 2015 A1
20160101287 Perryman Apr 2016 A1
20160136438 Perryman et al. May 2016 A1
20160136439 Andresen et al. May 2016 A1
20160339258 Perryman et al. Nov 2016 A1
20160361535 Perryman et al. Dec 2016 A1
20160367825 Perryman et al. Dec 2016 A1
20170036033 Perryman et al. Feb 2017 A9
20180008828 Perryman Jan 2018 A1
20180169423 Larson et al. Jun 2018 A1
20180236248 Perryman Aug 2018 A1
20180264277 Perryman Sep 2018 A1
20190229771 Lee et al. Jul 2019 A1
20190247660 Perryman Aug 2019 A1
20190381327 Perryman et al. Dec 2019 A1
20200016415 Perryman et al. Jan 2020 A1
20200016416 Perryman et al. Jan 2020 A1
20200222703 Perryman et al. Jul 2020 A1
20210275813 Perryman et al. Sep 2021 A1
20220088398 Perryman et al. Mar 2022 A1
20220126105 Penyman et al. Apr 2022 A1
Foreign Referenced Citations (43)
Number Date Country
1678370 Oct 2005 CN
101185789 May 2008 CN
101217320 Jul 2008 CN
101352596 Jan 2009 CN
101773701 Jul 2010 CN
101842131 Sep 2010 CN
201676401 Dec 2010 CN
102120060 Jul 2011 CN
2462981 Jun 2001 EP
1588609 Oct 2005 EP
2694154 Jan 2018 EP
2341347 Jun 2010 ES
H10 509901 Sep 1998 JP
2002524124 Aug 2002 JP
2005531371 Oct 2005 JP
2008023353 Feb 2008 JP
2008161667 Jul 2008 JP
2008528222 Jul 2008 JP
2009523402 Jun 2009 JP
2010534114 Nov 2010 JP
201155912 Mar 2011 JP
2011510787 Apr 2011 JP
2012508624 Apr 2012 JP
WO 9620754 Jul 1996 WO
WO 2000013585 Mar 2000 WO
WO 2004002572 Jan 2004 WO
WO 2004004826 Jan 2004 WO
WO 2006113802 Oct 2006 WO
WO2006128037 Nov 2006 WO
WO 2007059386 May 2007 WO
WO 2007081971 Jul 2007 WO
WO 2009015005 Jan 2009 WO
WO 2010005746 Jan 2010 WO
WO 2010051189 May 2010 WO
WO 2010053789 May 2010 WO
WO 2010057046 May 2010 WO
WO 2010104569 Sep 2010 WO
WO 2011079309 Jun 2011 WO
WO 2012103519 Aug 2012 WO
WO 2012138782 Oct 2012 WO
WO 2013019757 Feb 2013 WO
WO 2013025632 Feb 2013 WO
WO 2013040549 Mar 2013 WO
Non-Patent Literature Citations (40)
Entry
US 5,197,469 A, 03/1993, Adams (withdrawn)
Extended European Search Report in European Appln No. 20738285.4, dated Aug. 17, 2022, 5 pages.
U.S. Appl. No. 14/445,159, filed Nov. 13, 2014, Perryman et al.
U.S. Appl. No. 29/478,687, filed Jan. 7, 2003, Perryman et al.
CA Office Action in Canadian Appln. No. 2831138, dated Oct. 30, 2020, 4 pages.
CN OA in Chinese Appln. No. 201710675346.5, dated Jun. 1, 2020, 11 pages (with English translation).
EP European Search Report in European Appln. No. 12831083.6, dated Aug. 17, 2015, 9 pages.
EP European Search Report in European Appln. No. 17208566.4, dated Sep. 26, 2018, 10 pages.
EP Extended European Search Report in European Appln. No. 18150779.9, dated May 9, 2018, 7 pages.
EP Office Action in European Appln. No. 12740011.7, dated Sep. 18, 2018, 5 pages.
European Search Report in European Appln. No. 12767575.9, dated Jan. 11, 2018, 6 pages.
European Search Report in European Appln. No. 19186209, dated Nov. 25, 2019, 9 pages.
Extended European Search report in Appln. No. 12740011.7, dated Sep. 9, 2015, 6 pages.
Extended European Search report in Appln. No. 12767575.9, dated Nov. 7, 2014, 7 pages.
Extended European Search Report in Appln. No. 1281083.6, dated Aug. 17, 2015, 9 pages.
Extended European Search report in Appln. No. 12819482.6, dated Apr. 28, 2015, 7 pages.
Extended European Search Report in Appln. No. 12824347.4, dated Apr. 22, 2015, 6 pages.
Extended European Search Report in Appln. No. 15793285.6, dated Dec. 12, 2017, 7 pages.
Iannetta [online], “Nov. 2014 New Products: Wearable coil facilities positioning during prostate MRI,” Urology Times, retrieved on Nov. 10, 2014, retrieved from<URL: http://urologytimes.modernmedicine.com/urology-times/news/november-2014-new-products-wearable-coil-facilitates-positioning-during-prostate-mri?page=full>, 7 pages.
IL Office Action in Israeli Appln. No. 256280.0, dated Sep. 16, 2020, 9 pages (with English Translation).
O'Driscoll et al., “A mm-Sized implantable power receiver with adaptive link compensation.” Poster, Presented at IEEE International Solid-State Circuits Conference, Session 17, 2009, 3 pages.
PCT International Preliminary Report on Patentability and Written Opinion in International Appln. No. PCT/US2012/023029, dated Jan. 28, 2014, 10 pages.
PCT International Preliminary Report on Patentability and Written Opinion in International Appln. No. PCT/US2012/032200 dated Oct. 8, 2013, 11 pages.
PCT International Preliminary Report on Patentability and Written Opinion in International Appln. No. PCT/US2012/048903, dated Mar. 25, 2014, 8 pages.
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2013/077846, dated Jun. 30, 2015, 6 pages.
PCT International Preliminary Report on Patentability issued in International Appl. No. PCT/US2012/055746, dated Jan. 2, 2013, 10 pages.
PCT International Preliminary Report on Patentability issued in International Appln. No. PCT/US2012/050633, dated Feb. 18, 2014, 7 pages.
PCT International Search Report and PCT Written Opinion of the International Searching Authority in International Appln. No. PCT/US2012/055746, dated Jan. 3, 2013, 11 pages.
PCT International Search Report and the Written Opinion in Appln. No. PCT/US2012/048903 dated Oct. 10, 2012, 9 pages.
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2012/023029, dated May 16, 2012, 10 pages.
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2012/032200, dated Jul. 27, 2012, 12 pages.
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2012/050633 dated Oct. 23, 2012, 7 pages.
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2013/077846 dated Apr. 21, 2014, 10 pages.
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/013155, dated Apr. 1, 2020, 8 pages.
pharad.com [online], “Assembly, Wearable Antenna, 350-450 MHz,” retrieved on Oct. 14, 2010, retrieved from URL< http://www.pharad.com/pdf/UHF-Wearable-Antenna-2D.pdf>, 1 page.
Poon et al., “Optimal frequency for wireless power transmission into dispersive tissue,” IEEE Transactions on Antennas and Propagation, May 2010, 58(5):1739-1750.
wirelessdesignmag.com [online], “Pharad at Forefront of LTE Antenna Innovation with Development of LTE Wearable Antenna,” retrieved on Aug. 12, 2012, retrieved from<URL:http://www.wirelessdesignmag.com/product-release/2013/08/pharad-forefront-lte-antenna-innovation-development-lte-wearable-antenna>, 3 pages.
EP Extended European Search Report in European Appln. No. 20209052.8, dated Apr. 14, 2021, 7 pages.
International Preliminary Report on Patentability in International Appln. No. PCT/US2020/013155, dated Jul. 22, 2021, 8 pages.
Search Report in European Appln. No. 21164580.9, dated Oct. 22, 2021, 8 pages.
Related Publications (1)
Number Date Country
20210187311 A1 Jun 2021 US
Provisional Applications (1)
Number Date Country
61535295 Sep 2011 US
Continuations (3)
Number Date Country
Parent 15983355 May 2018 US
Child 17193191 US
Parent 15002610 Jan 2016 US
Child 15983355 US
Parent 13621530 Sep 2012 US
Child 15002610 US